PBYI (Puma Biotechnology) Change In Payables And Accrued Expense: $10.8 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBYI Puma Biotechnology Inc PBYI
53 GF Score
Price $9.05
GF Value $3.58
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Puma Biotechnology Change In Payables And Accrued Expense?

Puma Biotechnology PBYI -3.67% 53 Change In Payables And Accrued Expense is $10.8 Mil as of Jun. 2026. GuruFocus rates PBYI with a GF Score™ of 53/100 and a GF Value™ of $3.58 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Puma Biotechnology's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2026 was $1.6 Mil. It means Puma Biotechnology's Accounts Payable & Accrued Expense increased by $1.6 Mil from Mar. 2026 to Jun. 2026 .

Puma Biotechnology's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2025 was $12.7 Mil. It means Puma Biotechnology's Accounts Payable & Accrued Expense increased by $12.7 Mil from Dec. 2024 to Dec. 2025 .

Puma Biotechnology Change In Payables And Accrued Expense Historical Data

* Premium members only.

The historical data trend for Puma Biotechnology's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Puma Biotechnology Change In Payables And Accrued Expense Chart

Puma Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Payables And Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.31 -37.80 -7.13 -17.20 12.70

Puma Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.28 6.24 11.55 -8.58 1.59
PBYI
53GF Score
Puma Biotechnology Inc PBYI
Change In Payables And Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Puma Biotechnology Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $10.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Change In Payables And Accrued Expense of $10.8 Mil mean?
Puma Biotechnology (PBYI) has a Change In Payables And Accrued Expense of $10.8 Mil as of Jun. 2026. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Puma Biotechnology and its competitors.
Is Puma Biotechnology's Change In Payables And Accrued Expense too high?
Puma Biotechnology's current Change In Payables And Accrued Expense is $10.8 Mil. Overall, Puma Biotechnology has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Puma Biotechnology's Change In Payables And Accrued Expense compare to DNA and CCCC?
Puma Biotechnology's Change In Payables And Accrued Expense of $10.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Payables And Accrued Expense for a Biotechnology company?
A good Change In Payables And Accrued Expense depends on the Biotechnology industry context. However, Change In Payables And Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Payables And Accrued Expense mean?
A high Change In Payables And Accrued Expense can signal that a stock is expensive relative to its fundamentals. Change In Payables And Accrued Expense is any increase or decrease between periods of the payables and accrued expense. View historical data on Puma Biotechnology and its competitors. Puma Biotechnology's current Change In Payables And Accrued Expense is $10.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Puma Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Puma Biotechnology (PBYI) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.58, compared to a current price of $9.05 — trading 152.7% above its estimated fair value. The current Change In Payables And Accrued Expense is $10.8 Mil. Puma Biotechnology's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Payables And Accrued Expense calculated?
Change In Payables And Accrued Expense is calculated from a company's financial statements. For Puma Biotechnology (PBYI), the current Change In Payables And Accrued Expense is $10.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Puma Biotechnology (PBYI) Overvalued in 2026?

Based on GuruFocus' analysis, Puma Biotechnology stock appears to be overvalued. The current stock price of $9.05 is trading 152.7% above its estimated GF Value™ of $3.58. GuruFocus considers Puma Biotechnology to be Significantly Overvalued.

Key valuation signals for PBYI:

  • Change In Payables And Accrued Expense: $10.8 Mil
  • GF Value™: $3.58 vs. price of $9.05 (152.7% above fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the PBYI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Puma Biotechnology Business Description

Address 10880 Wilshire Boulevard, Suite 1700, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
53GF Score

Get the complete analysis for PBYI

Change In Payables And Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.05
Price
$3.58
GF Value